Crisis is cancer care

Article

Medicare only covers 57% of the actual costs of delivering chemotherapy and provided related infusion room services to seniors with cancer: Watch this important video: Cancer Care is in Crisis: Stop The Cancer Care Cuts

Medicare only covers 57% of the actual costs of delivering chemotherapy and provided related infusion room services to seniors with cancer: Watch this important video: Cancer Care is in Crisis: Stop The Cancer Care Cuts

The dreaded sustainable growth rate formula (SGR) that cuts physicians’ Medicare pay takes effect in 61 days (Dec. 1) but already the American Medical Association, 66 specialist practitioner societies and 50 state medical groups, are sounding the alarm.  Once again…

According to major cancer organizations such as the Community Oncology Alliance, (COA), if nothing is done, the 23% cut in physician fees Dec. 1, will be followed by another 6.5% cut Jan. 1, reductions that could seriously impair the ability of seniors to access care because many physicians who now accept Medicare beneficiaries will stop doing so.

Watch this video, and pass along to your collegues…

 

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content